WO2003099785A1 - Procede de preparation de calcium atorvastatine amorphe - Google Patents

Procede de preparation de calcium atorvastatine amorphe Download PDF

Info

Publication number
WO2003099785A1
WO2003099785A1 PCT/IN2002/000220 IN0200220W WO03099785A1 WO 2003099785 A1 WO2003099785 A1 WO 2003099785A1 IN 0200220 W IN0200220 W IN 0200220W WO 03099785 A1 WO03099785 A1 WO 03099785A1
Authority
WO
WIPO (PCT)
Prior art keywords
atorvastatin calcium
acetone
solvent
amorphous
volumes
Prior art date
Application number
PCT/IN2002/000220
Other languages
English (en)
Inventor
Virendra Kumar Agarwal
Manish Harshadbhai Vakil
Kanwal Pandita
Satish Champaklal Manakiwala
Pankaj Ramanbhai Patel
Original Assignee
Cadila Healthcare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Limited filed Critical Cadila Healthcare Limited
Priority to AU2002356423A priority Critical patent/AU2002356423A1/en
Publication of WO2003099785A1 publication Critical patent/WO2003099785A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Definitions

  • the present invention relates to a process for the production of amorphous atorvastatin calcium.
  • Atorvastatin the substance known by the chemical name [R-(R*,R*)]-2-( 4- FLUOROPHENYL)- ⁇ , ⁇ -DmYDROXY-5-(l-METHYLETHYL) PHENYL-4-
  • statins [(PHENYLAMINO) CARBONYL]-lH-PYRROLE-l-HEPTA OIC ACID is a member of the class of drugs called statins.
  • Statin drugs are currently the most therapeutically effective drugs available for the treatment of hyperlipidemia and hypercholesterolemia, both of which are risk factors for arteriosclerosis and coronary heart disease. Open dihydroxy carboxylic acid, lactone and various salt forms of atorvastatin have been synthesized.
  • R-form of the ring opened acid form has surprising inhibition of the biosynthesis of cholesterol.
  • Atorvastatin in its calcium salt form i.e. [R-(R*,R*)]-2-(4-fluorophenyl)- ⁇ , ⁇ -dihydroxy-5- ( 1 -methyl ethyl)-3 -phenyl-4-[(phenylamino)carbonyl] - 1 H-pyrrole- 1 -heptanoic acid calcium salt (2: 1) having formula 1 is more suited for formulations and has been recommended as a drug.
  • Atorvastatin is preferably prepared as its calcium salt, i.e.
  • the amorphous forms in a number of pharmaceutical substances exhibit different dissolution characteristics and bioavailability patterns compared to crystalline forms (Knno T. Chem. Pharm. Bull. 1990, 38, 2003-2007).
  • the bioavailability is one of the key parameters determining the form of the susbstance to be used in a pharmaceutical formulation. Since process for the crystallization and the preparation, respectively of the amorphous substance are sometimes difficult to be performed and as a result the product obtained is in a mixture of amorphous and crystalline form. There is a constant need for processes which enable the preparation of atorvastatin in an amorphous form without simultaneous formation of crystalline forms or which will enable the conversion of crystalline forms into the amorphous form.
  • Atorvastatin calcium is very slightly soluble in water and it has been found that the crystalline form is less readily soluble than the amorphous form, which may cause problems in the bioavailability of atorvastatin. It has been found that the production of amorphous atorvastatin accordingly to the previously disclosed processes was not consistently reproducible. Therefore various processes have been developed for converting the crystalline form in to amorphous form.
  • WO 97/03960 describes a procedure for converting the crystalline form of atorvastatin calcium to the amorphous form.
  • Process disclosed therein comprises dissolving crystalline form I atorvastatin in a non-hydroxylitic solvent like tetrahydrofuran or mixture of tetrahydrofuran and toluene.
  • the process involves complete removal of the solvent under high temperature (about 90°c) and under high vacuum (about 5 mm) for 3-5 days. Exposure of the material to high temperature for several days may lead to degradation of the product. This makes the process very inconvenient to operate on a large scale. Slow removal of solvent at a manufacturing scale renders this process as less productive.
  • amorphous atorvastatin described in WO 00/71116 involves dissolving crystalline form in tetrahydrofuran and reprecipitating amorphous atorvastatin by adding cyclohexane or n-hexane n-heptane.
  • WO 01/28999 describes the purification of crude amorphous atorvastatin calcium by dissolving crude amorphous material in large excess of boiling ethanol or 2-propanol and filtering the hot solution and recovering the material at low temperature.
  • WO 01/42209 describes the preparation of amorphous atorvastatin calcium from form I by dissolving crystalline form in about 20 - 25 times of methanol, ethanol or acetone, concentrating the solution by distillation and precipitating the product by adding diethylether.
  • the process disclosed therein also is not recommended for commercial production of amorphous atorvastatin calcium due to the use of large excess of diethylether, which may not be safe on plant level.
  • amorphous atorvastatin calcium The procedures to manufacture amorphous atorvastatin calcium disclosed in prior arts employ a large excess of solvent or a mixture of solvents, and removing the solvents at high temperature for a longer period of time. Laboratory trials conducted based on all prior arts give amorphous atorvastatin calcium accompanied with higher level of residual solvents i.e. 10,000 to 20,000 ppm, the level of residual solvents is not reduced even at higher temperature under vacuum. The prolonged heating to reduce the level of residual solvents did not result in decrease of the level of residual solvents, instead an appreciable degradation of the product was observed.
  • the above object is achieved by process of the invention, which employs a single solvent of aliphatic acyclic ketone group, and the level of residual solvent in final product is less than 5000 ppm which is easily achieved by drying the product at relatively less temperature i.e. 45 to 50 °C under vacuum for 10 to 15 hours.
  • the amorphous atorvastatin calcium prepared by the process disclosed herein does not show any degradation of the product.
  • amorphous atorvastatin calcium is produced by dissolving form - I or a mixture of crystalline and amorphous atorvastatin calcium in aliphatic acyclic ketones filtering the solution and removing the solvent at 45 to 50 °C under vacuum till desired level of residual solvent below 5000 ppm is achieved providing pure amorphous atorvastatin calcium as revealed by X-ray powder difractogram.
  • the solvent is selected from acetone, 2-butanone, 3-pentanone, 2- pentanone or 2-hexanone.
  • Acetone is the most preferred solvent due to its lowest boiling point i.e. 56 °C as compared to other aliphatic acyclic ketones.
  • Employing acetone as a solvent gives desired level of residual solvent in final product at relatively low temperature i.e. 45 to 50°C under vacuum for 10 to 15 hours, while other aliphatic acyclic ketones gives higher level of residual solvents even at higher temperature under vacuum for prolonged heating.
  • Atorvastatin calcium form - 1 can easily be dissolved in 10 - 15 volumes of acetone at 45 - 50 °C while a mixture of crystalline and amorphous atorvastatin calcium requires 30 - 50 volumes of acetone depending on the composition of crystalline and amorphous atorvastatin calcium in a particular mixture.
  • the invention disclosed herein gives pure amorphous atorvastatin calcium by using atorvastatin calcium form - I or any mixture of crystalline and amorphous atorvastatin calcium demonstrating the wide scope and capability of the process disclosed herein. Detailed description of the invention
  • form - I of atorvastatin calcium is dissolved in 15 volumes of acetone at 40 - 45 °C and the solution is filtered to remove suspended and extraneous material.
  • the filtered solution is concentrated at 45 - 50 °C under vacuum leaving behind approximately 2.5 - 3 volumes of acetone.
  • the concentrated solution of atorvastatin calcium in acetone is placed on glass tray, which is put in vacuum dryer.
  • the remaining acetone is removed at 45 - 50 °C under vacuum for 2 - 3 hours resulting in the white flakes of amorphous atorvastatin calcium which is uniformly powdered.
  • the powdered amorphous atorvastatin calcium is dried at 45 - 50 °C under vacuum for 15 hours to get acetone content in final product less than 5000 ppm.
  • X-ray powder difractogram reveals the material to be completely amorphous (figure - 2)
  • a mixture of crystalline and amorphous atorvastatin calcium is dissolved at 50 - 55 °C in 30 - 50 volumes of acetone depending on the composition of crystalline and amorphous atorvastatin calcium in the mixture.
  • the solution is filtered to remove suspended particles and extraneous material.
  • the filtered solution is concentrated at 45 - 50 °C under vacuum leaving behind approximately 2.5 - 3 volumes of acetone.
  • the concentrated solution of atorvastatin calcium in acetone is placed on glass tray, which is put in vacuum dryer. The remaining acetone is removed at 45 - 50 °C under vacuum for 2 - 3 hours resulting in the white flakes of amorphous atorvastatin calcium, which is uniformly powdered.
  • the powdered amorphous atorvastatin calcium is dried at 45 - 50 °C under vacuum for 15 hours to get acetone content in final product less than 5000 ppm.
  • X-ray powder difractogram reveals the material to be completely amorphous (figure - 4)
  • Figure 1 depicts X-ray Powder difractogram of atorvastatin calcium form - I.
  • the horizontal axis presents 2 ⁇ and the vertical axis corresponds to peak intensity.
  • Figures 2 depicts X-ray powder difractogram of amorphous atorvastatin calcium.
  • the horizontal axis presents 2 ⁇ and the vertical axis corresponds to peak intensity.
  • Figures 3 depicts X-ray powder difractogram of mixture of crystalline and amorphous atorvastatin calcium.
  • the horizontal axis presents 2 ⁇ and the vertical axis corresponds to peak intensity.
  • Figures 4 depicts X-ray powder difractogram of amorphous atorvastatin calcium. The horizontal axis presents 2 ⁇ and the vertical axis corresponds to peak intensity.
  • Example 2 10 g of a mixture of crystalline and amorphous Atorvastatin calcium was dissolved in 500 ml of acetone at 50 to 55 °C. The solution was filtered and acetone was removed by vacuum distillation at 45 to 50 °C leaving behind approximately 30 ml of acetone. The concentrated solution of atorvastatin calcium in acetone was further dried in vacuum oven at 45 to 50 °C for 3 hours providing white flakes of amorphous atorvastatin calcium which was uniformly powdered. The powdered amorphous atorvastatin calcium was dried at 45 - 50 °C under vacuum for 15 hours to give 8.5 g white solid material with acetone content in final product less than 5000 ppm. X-ray powder difractogram reveals the material to be completely amorphous (figure - 4).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

L'invention concerne un procédé de préparation de calcium atorvastatine amorphe. Ce procédé consiste essentiellement à dissoudre une forme - I ou un mélange de calcium atorvastatine cristallin et amorphe dans un solvant constitué d'une cétone acyclique aliphatique; à filtrer la solution; et à éliminer le solvant entre 40 et 50 °C sous vide.
PCT/IN2002/000220 2002-05-28 2002-11-15 Procede de preparation de calcium atorvastatine amorphe WO2003099785A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002356423A AU2002356423A1 (en) 2002-05-28 2002-11-15 Process for the preparation of amorphous atorvastatin calcium

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN472/MUM/2002 2002-05-28
IN472MU2002 2002-05-28

Publications (1)

Publication Number Publication Date
WO2003099785A1 true WO2003099785A1 (fr) 2003-12-04

Family

ID=29560492

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2002/000220 WO2003099785A1 (fr) 2002-05-28 2002-11-15 Procede de preparation de calcium atorvastatine amorphe

Country Status (3)

Country Link
AU (1) AU2002356423A1 (fr)
PL (1) PL357490A1 (fr)
WO (1) WO2003099785A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006012499A2 (fr) * 2004-07-22 2006-02-02 Teva Pharmaceutical Industries Ltd. Nouvelles formes cristallines d'hemi-calcium d'atorvastatine et leurs procedes de preparation
WO2006021969A1 (fr) * 2004-08-27 2006-03-02 Biocon Limited Processus pour calcium d'atorvastatine amorphe
WO2006045018A1 (fr) 2004-10-18 2006-04-27 Teva Pharmaceutical Industries Ltd. Procede d'elaboration d'hemicalcium d'atorvastatine amorphe par dissolution du sel dans un solvant organique qui est un melange d'alcool et de cetone et/ou d'ester et elimination du solvant
US7151183B2 (en) * 2000-11-30 2006-12-19 Teva Pharmaceutical Industries Ltd. Processes for preparing amorphous atorvastatin hemi-calcium
EP2075246A1 (fr) 2007-12-27 2009-07-01 M. J. Institute of Research Procédé de préparation de forme amorphe de sel hémicalcium atorvastanine
US7994343B2 (en) 2004-03-17 2011-08-09 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003960A1 (fr) * 1995-07-17 1997-02-06 Warner-Lambert Company NOUVEAU PROCEDE POUR LA PRODUCTION DE SEL DE CALCIUM D'ACIDE AMORPHE [R-(R*,R*))-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-(PHENYLAMINO)CARBONYLE]-1H-PYRROL-1-HEPTANOIQUE (2:1)
WO2000071116A1 (fr) * 1999-05-25 2000-11-30 Ranbaxy Laboratories Limited Procede relatif a la production de calcium d'atorvastatine amorphe
WO2001028999A1 (fr) * 1999-10-18 2001-04-26 EGIS Gyógyszergyár Rt. Procede de preparation d'atorvastatine calcique amorphe
WO2001042209A1 (fr) * 1999-12-10 2001-06-14 Lek Pharmaceutical And Chemical Company D.D. Procede de preparation d'atorvastatine amorphe
WO2002043732A1 (fr) * 2000-11-30 2002-06-06 Teva Pharmaceutical Industries Ltd. Nouvelles formes cristallines d'hemi-calcium d'atorvastatine et leurs procedes de preparation, et nouveaux procedes de preparation d'autres formes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003960A1 (fr) * 1995-07-17 1997-02-06 Warner-Lambert Company NOUVEAU PROCEDE POUR LA PRODUCTION DE SEL DE CALCIUM D'ACIDE AMORPHE [R-(R*,R*))-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-(PHENYLAMINO)CARBONYLE]-1H-PYRROL-1-HEPTANOIQUE (2:1)
WO2000071116A1 (fr) * 1999-05-25 2000-11-30 Ranbaxy Laboratories Limited Procede relatif a la production de calcium d'atorvastatine amorphe
WO2001028999A1 (fr) * 1999-10-18 2001-04-26 EGIS Gyógyszergyár Rt. Procede de preparation d'atorvastatine calcique amorphe
WO2001042209A1 (fr) * 1999-12-10 2001-06-14 Lek Pharmaceutical And Chemical Company D.D. Procede de preparation d'atorvastatine amorphe
WO2002043732A1 (fr) * 2000-11-30 2002-06-06 Teva Pharmaceutical Industries Ltd. Nouvelles formes cristallines d'hemi-calcium d'atorvastatine et leurs procedes de preparation, et nouveaux procedes de preparation d'autres formes

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151183B2 (en) * 2000-11-30 2006-12-19 Teva Pharmaceutical Industries Ltd. Processes for preparing amorphous atorvastatin hemi-calcium
US7994343B2 (en) 2004-03-17 2011-08-09 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
WO2006012499A2 (fr) * 2004-07-22 2006-02-02 Teva Pharmaceutical Industries Ltd. Nouvelles formes cristallines d'hemi-calcium d'atorvastatine et leurs procedes de preparation
WO2006012499A3 (fr) * 2004-07-22 2006-07-20 Teva Pharma Nouvelles formes cristallines d'hemi-calcium d'atorvastatine et leurs procedes de preparation
WO2006021969A1 (fr) * 2004-08-27 2006-03-02 Biocon Limited Processus pour calcium d'atorvastatine amorphe
US7645888B2 (en) 2004-08-27 2010-01-12 Biocon Limited Process for the production of amorphous atorvastatin calcium
WO2006045018A1 (fr) 2004-10-18 2006-04-27 Teva Pharmaceutical Industries Ltd. Procede d'elaboration d'hemicalcium d'atorvastatine amorphe par dissolution du sel dans un solvant organique qui est un melange d'alcool et de cetone et/ou d'ester et elimination du solvant
US20060106230A1 (en) * 2004-10-18 2006-05-18 Michael Pinchasov Processes for preparing amorphous atorvastatin hemi-calcium
JP2007515430A (ja) * 2004-10-18 2007-06-14 テバ ファーマシューティカル インダストリーズ リミティド アルコール及びケトン、及び／又はエステルの混合物である有機溶媒に塩を溶解し、そして溶媒を除去することにより非晶質アトルバスタチンへミ−カルシウムの調製方法
EP2075246A1 (fr) 2007-12-27 2009-07-01 M. J. Institute of Research Procédé de préparation de forme amorphe de sel hémicalcium atorvastanine

Also Published As

Publication number Publication date
AU2002356423A1 (en) 2003-12-12
PL357490A1 (en) 2003-12-01

Similar Documents

Publication Publication Date Title
US6528660B1 (en) Process for the production of amorphous atorvastatin calcium
US7189861B2 (en) Processes for preparing amorphous atorvastatin hemi-calcium
KR100729689B1 (ko) 비결정형의 아토르바스타틴의 제조방법
RU2255932C2 (ru) Способ получения аморфного аторвастатина кальция
US20090143459A1 (en) Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002083637A1 (fr) Procede de production d'atorvastatine calcique sous forme amorphe
JP2009235083A (ja) アトルバスタチンヘミカルシウムの新規結晶形態およびその調製方法ならびにアトルバスタチンヘミカルシウム形態ｉ、ｖｉｉｉおよびｉｘの新規調製方法
IL155734A (en) Form 7 of atorvastatin mycalcium
JP2006503024A (ja) Ｖｉ型アトルバスタチンカルシウムまたはその水和物
WO2003099785A1 (fr) Procede de preparation de calcium atorvastatine amorphe
KR20080015510A (ko) 저장 후 안정한 아토르바스타틴 칼슘의 결정형
EA013500B1 (ru) Способ получения аморфной кальциевой соли аторвастатина
WO2005073187A1 (fr) Procede ameliore de preparation d'atorvastatine calcique amorphe
US20060020137A1 (en) Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
RU2344127C2 (ru) Новые кристаллические структуры (полиморфные модификации) полукальциевой соли аторвастатина и способы получения этих и других полиморфных модификаций соли аторвастатина
US20050165242A1 (en) Process for the preparation of amorphous atorvastatin calcium
AU2007205725A1 (en) Novel cyrstal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US20040063969A1 (en) Process for the preparation of amorphous atorvastatin calcium
MX2008000375A (en) Crystalline form of atorvastatin calcium stable after storage
WO2006048888A1 (fr) Nouveau procede de preparation du sel de calcium d’atorvastatine amorphe
CZ2005573A3 (cs) Zpusob výroby krystalické formy hemivápenaté soli(3R, 5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorofenyl)-5-isopropylpyrrol-1-y-1]-3,5 dihydroxyheptanové kyseliny (atorvastatinu)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP